ArticleOncology (Williston Park, N.Y.)2013
Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
Article in Oncology (Williston Park, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Investigating the role of prognostic mitophagy-related genes in non-small cell cancer pathogenesis via multiomics and network-based approach.3 Biotech · 2024Article
- Label-free quantitative identification of abnormally ubiquitinated proteins as useful biomarkers for human lung squamous cell carcinomas.The EPMA journal · 2020Article
- Identification of Hub Genes Related to Carcinogenesis and Prognosis in Colorectal Cancer Based on Integrated Bioinformatics.Mediators of inflammation · 2020Article
- Colorectal Cancer Prognosis is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study.Journal of clinical medicine · 2019Article
- Article
- Validation and Clinical Applications of a Comprehensive Next Generation Sequencing System for Molecular Characterization of Solid Cancer Tissues.Frontiers in molecular biosciences · 2019Article
- Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges.Annals of translational medicine · 2017Review
- Future paradigms for precision oncology.Oncotarget · 2016Review
- Screening of Target Genes and Regulatory Function of miRNAs as Prognostic Indicators for Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- The impact of the Cancer Genome Atlas on lung cancer.Translational research : the journal of laboratory and clinical medicine · 2015Review
- 50 Years of progress in the systemic therapy of non-small cell lung cancer.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2014Review
- Do oncogenic drivers exist in squamous cell carcinoma of the lung?Oncology (Williston Park, N.Y.) · 2013Article
- Moonshot Objectives: Catalyze New Scientific Breakthroughs-Proteogenomics.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Very little progress has been made in the treatment of patients with metastatic squamous cell lung cancer over the past 2 decades. Identification of novel molecular alterations for targeted therapies is necessary to improve outcomes. Advances in genomic technology have now made it possible to analyze the genomic landscape of tumor tissues comprehensively. We summarize here key findings from the comprehensive analysis of squamous cell lung cancer by The Cancer Genome Atlas group and discuss the clinical implications of these findings.
Indexed as
Identifiers
24282988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.